Harrow Health Inc Stock Price, News & Analysis

ImprimisRx, America’s leading Ophthalmic Pharmacy™, has launched Fortisite™, a compounded topical antibiotic formulated with Tobramycin 1.5% and Vancomycin 5%. This unique formulation is stable at refrigerated temperatures for up to 180 days and aims to meet unmet clinical needs. Available through the ImprimisRx 503A pharmacy now, it will soon be accessible via the FDA-registered 503B outsourcing facility. A Patient Access Program and a 100% replacement guarantee for expired products further enhance accessibility for eyecare professionals.

IHEEZO™ (chloroprocaine hydrochloride ophthalmic gel) has received FDA approval, marking the first branded ocular anesthetic in the U.S. in nearly 14 years. Licensed by Harrow from Sintetica, IHEEZO is designed for ocular surface anesthesia and boasts a patent protecting it until 2038. Its clinical studies showed rapid action and effective anesthesia for cataract surgeries, without the need for supplemental treatments. With an estimated 4.5 million cataract surgeries annually in the U.S., Harrow aims for an accelerated commercial launch, enhancing its market presence in the ophthalmic sector.

Harrow Health, Inc. (Nasdaq: HROW), a pharmaceutical company specializing in eyecare, announced participation in the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference on August 17, 2022. CEO Mark L. Baum and CFO Andrew Boll will represent the company. A pre-recorded presentation will be available on Harrow's investor relations webpage starting at 7:00 a.m. ET on that date and archived for 90 days. Additionally, management will engage in one-on-one meetings during the conference, which interested investors can request through H.C. Wainwright.

Harrow Health, Inc. (NASDAQ: HROW) reported record revenues of $23.3 million for Q2 2022, a 29% increase from $18.1 million the previous year. The gross profit also hit a record at $16.8 million, a 22% rise from $13.7 million year-over-year. The company shipped 718,000 product units, which is a 4% year-over-year increase. However, Harrow reported a net loss of $6.2 million compared to $3 million last year. Cash and cash equivalents stood at $46.4 million as of June 30, 2022, as the company looks forward to key events in the second half of the year.

Harrow Health, Inc. (Nasdaq: HROW) will release its financial results for Q2 ended June 30, 2022 on August 9, 2022, after market close. A Letter to Stockholders will be available on its website. Following this, a conference call will occur at 4:45 p.m. ET to discuss the results and provide a business update. Investors can participate through dial-in or via live webcast. The telephonic replay will be available until August 16, 2022, and the webcast replay until November 9, 2022.

Harrow Health, Inc. (NASDAQ: HROW) has successfully transferred the New Drug Applications (NDAs) for three FDA-approved ophthalmic medicines: IOPIDINE® 1%, MAXITROL® 3.5mg/10,000 units/0.1%, and MOXEZA® 0.5%. Both IOPIDINE 1% and MAXITROL are now commercially available, with MOXEZA set for later release. This move follows their acquisition of these products in December 2021, during which Harrow began receiving net profits from sales. CEO Mark L. Baum expressed optimism about market interest and plans for commercial strategies targeting healthcare professionals and payers.

Harrow Health (NASDAQ: HROW) reported a record revenue of $22.1 million for Q1 2022, marking a 43% increase from $15.4 million in Q1 2021. The gross profit reached $16.2 million, up 38% year-over-year. A total of 689,000 product units were shipped, a 72% increase from the prior year. Despite a net loss of $2.4 million, the company anticipates a strong year driven by organic growth and plans for AMP-100's FDA review on October 16, 2022. Cash and equivalents stood at $42 million as of March 31, 2022.

Melt Pharmaceuticals announced favorable top-line results from its phase 1 PK study of MELT-210, a 3 mg sublingual midazolam tablet. The study involving 23 patients compared MELT-210 with IV midazolam and achieved concentration goals. CEO Larry Dillaha expressed optimism about the results, viewing it as a milestone for an IV-free sedation option. The next step includes discussions with the FDA regarding further clinical development. MELT-210 utilizes Catalent's proprietary Zydis® technology, with no FDA-approved equivalent products.

NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow Health, Inc. (NASDAQ: HROW) announced participation in B. Riley Securities' Annual Neuro & Ophthalmology Investor Conference. CEO Mark L. Baum and CFO Andrew Boll will present virtually on April 27, 2022, at 2:00 p.m. ET. A live webcast will be accessible on Harrow's website, with a replay available post-event. Harrow Health focuses on ophthalmic healthcare, owning ImprimisRx and Visionology, and holds equity in Eton Pharmaceuticals, Surface Ophthalmics, and Melt Pharmaceuticals.